Early Phase 1 Melanoma Trial, Recruiting NCT04741997 Sponsor: H. Lee Moffitt Cancer Center and Research Institute Condition: Melanoma
Back to Melanoma

Early Phase 1 Melanoma Trial, Recruiting

NCT04741997
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older when you sign the consent form
  • You must have been diagnosed with melanoma (confirmed by a tissue sample), from any location on the body or of unknown origin
  • Your melanoma must have a specific gene change called a BRAFV600 mutation, and must be at an advanced stage (Stage III B/C/D or Stage IV)
  • You must be well enough to carry out basic daily activities (your doctor will assess this using a standard scale)
  • Your blood test results must show acceptable levels of red blood cells, platelets, liver function, and kidney function
  • If you could become pregnant, you must have a negative pregnancy test and agree to use highly effective non-hormonal contraception during the trial
  • If you are male, you must agree to use highly effective contraception during the trial
  • You may have previously received certain immunotherapy treatments (anti-PD-1/PD-L1 or CTLA-4 inhibitors)
  • People living with HIV may be eligible if they are on effective treatment and their virus levels are undetectable
  • People with a history of hepatitis C may be eligible if they have been successfully treated and cured, or have undetectable virus levels if currently being treated

Who may not be able to join:

  • You are not eligible if your melanoma got worse while you were actively taking BRAF or MEK inhibitor drugs (though progressing after stopping those drugs may be permitted)
  • You cannot join if you previously had to stop taking the specific study drugs (encorafenib and/or binimetinib) due to serious side effects
  • You cannot join if you have had major surgery or radiation treatment within the last 14 days, or have not yet recovered from those procedures
  • You cannot join if you are unwilling to avoid grapefruit, pomegranates, star fruit, Seville oranges, or their juices during the study
  • You cannot join if you have brain tumours that are unstable, causing symptoms, require steroid treatment, or have been treated with radiation within the last 28 days (confirm with trial site)
  • You cannot join if you have certain serious heart problems, including severe heart failure, uncontrolled irregular heart rhythms, or an abnormal heart electrical reading above a certain level
  • You cannot join if you have a known history of a blood clot in the eye (retinal vein occlusion)
  • You cannot join if you are currently taking, or have recently taken within the past week, any medications, herbal supplements, or foods that are not permitted in this trial (confirm with trial site for the full list)
  • You cannot join if you are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Zeynep Eroglu, MD, Moffitt Cancer Center

Phone: 813-745-5938

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
24 May 2021
Est. completion
22 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of Disease Relapse

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov